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Key messages
 ► Is nintedanib therapy well tolerated in patients with 
idiopathic pulmonary fibrosis (IPF) and does it im-
prove survival?
 ► Data from 1126 patients with IPF participating in 
prospective clinical trials showed that the adverse 
event profile of nintedanib was manageable for most 
patients; extrapolation of survival data suggested 
that nintedanib extends life expectancy.
 ► This is the largest data set on nintedanib to be pub-
lished to date and the first analyses to estimate life 
expectancy in patients with IPF treated with nin-
tedanib based on extrapolation of survival data from 
clinical trials.
AbstrAct
Introduction Nintedanib slows disease progression 
in patients with idiopathic pulmonary fibrosis (IPF) by 
reducing the rate of decline in forced vital capacity, with an 
adverse event profile that is manageable for most patients. 
We used data from six clinical trials to characterise 
the safety and tolerability profile of nintedanib and to 
investigate its effects on survival.
Methods Data from patients treated with ≥1 dose of 
nintedanib 150 mg two times per day or placebo in the 
52-week TOMORROW trial and/or its open-label extension; 
the two 52-week INPULSIS trials and/or their open-label 
extension, INPULSIS-ON; and a Phase IIIb trial with a 
placebo-controlled period of ≥6 months followed by 
open-label nintedanib were pooled. All adverse events, 
irrespective of causality, were included in descriptive 
analyses. Parametric survival distributions were fit to 
pooled Kaplan-Meier survival data from the trials and 
extrapolated to estimate long-term survival.
results There were 1126 patients in the pooled 
nintedanib group and 565 patients in the pooled placebo 
group. The mean duration of nintedanib treatment 
was 28 months. No new safety signals were observed. 
Incidence rates of bleeding, liver enzyme elevations 
and cardiovascular events were consistent with those 
observed in the INPULSIS trials. Diarrhoea was reported 
at a lower event rate in the pooled nintedanib group than 
in nintedanib-treated patients in the INPULSIS trials (76.5 
vs 112.6 events per 100 patient exposure-years) and 
infrequently led to permanent treatment discontinuation 
(3.6 events per 100 patient exposure-years). Based on the 
Weibull distribution, mean (95% CI) survival was estimated 
as 11.6 (9.6, 14.1) years in nintedanib-treated patients and 
3.7 (2.5, 5.4) years in placebo-treated patients.
conclusions Based on pooled data from six clinical 
trials, the adverse event profile of nintedanib was 
manageable for most patients. Exploratory analyses based 
on extrapolation of survival data suggest that nintedanib 
extends life expectancy in patients with IPF.
IntroductIon
Idiopathic pulmonary fibrosis (IPF) is an inter-
stitial lung disease associated with progressive 
loss of lung function, worsening dyspnoea 
and substantial impairment in quality of 
life.1 2 IPF has a variable clinical course but a 
poor prognosis. In patients not receiving anti-
fibrotic therapies, median survival following 
diagnosis of IPF is approximately 3–5 years.3–6
Nintedanib, an intracellular inhibitor of 
tyrosine kinases, is an approved treatment 
for IPF. The efficacy, safety and tolerability 
of nintedanib 150 mg two times per day 
in patients with IPF and mild or moderate 
impairment in lung function have been 
assessed in several international clinical trials: 
the Phase II TOMORROW trial7 and its open-
label extension8; the two replicate Phase 
III INPULSIS trials9 and their open-label 
extension INPULSIS-ON10; and an explor-
atory Phase IIIb trial.11 The results of these 
trials demonstrated that nintedanib reduces 
disease progression by slowing the rate of 
decline in forced vital capacity (FVC), with 
a side effect profile characterised mainly by 
gastrointestinal adverse events. Although no 
individual trial of nintedanib in patients with 
IPF has been powered to show a reduction in 
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mortality versus placebo, an analysis of pooled data from 
the TOMORROW and INPULSIS trials suggested that 
nintedanib was associated with a 30% reduction in the 
risk of mortality compared with placebo over 52 weeks 
of treatment (HR 0.70 [95% CI 0.46 to 1.08]; p=0.095).12
We used data from the six international Phase II/III 
trials of nintedanib conducted in patients with IPF and 
mild or moderate impairment in lung function7–11 to 
extend the characterisation of the safety and tolerability 
profile of nintedanib and to investigate its effects on 
survival in patients with IPF.
Methods
study design
The TOMORROW trial (NCT00514683) began with 
a 52-week period in which patients with IPF, FVC≥50% 
predicted and diffusing capacity of the lung for carbon 
monoxide (DLco) 30%–79% predicted were randomised 
to receive placebo or one of four doses of nintedanib 
(50 mg once daily, 50 mg two times per day, 100 mg two 
times per day, 150 mg two times per day).7 Patients who 
completed 52 weeks’ treatment in this period (period 
1) continued treatment in a blinded phase (period 2), 
until the last patient had completed 52 weeks’ treatment 
in period 1. This was followed by an open-label exten-
sion period in which all patients received nintedanib 
(NCT01170065).8 In each of the INPULSIS trials 
(NCT01335464 and NCT01335477), patients with IPF, 
FVC≥50% predicted and DLco 30%–79% predicted 
were randomised 3:2 to receive nintedanib 150 mg two 
times per day or placebo for 52 weeks.9 Patients who 
completed the 52-week treatment period and a follow-up 
visit 4 weeks later were eligible to receive open-label 
nintedanib in INPULSIS-ON (NCT01619085).10 In 
the Phase IIIb trial (NCT01979952), patients with IPF, 
FVC≥50% predicted and DLco 30%–79% predicted were 
originally randomised to receive nintedanib 150 mg two 
times per day or placebo double-blind for 12 months, 
but this was amended to a placebo-controlled period of 
6 months following regulatory approval of nintedanib in 
some participating countries. The double-blind period 
was ≥6 months for some patients due to the variable time 
required to implement the protocol amendment.11 In 
all these trials, dose reductions from 150 to 100 mg two 
times per day and treatment interruptions were allowed 
to manage adverse events. No dose re-escalations were 
permitted in the TOMORROW trial, but dose could be 
increased from 100 to 150 mg two times per day in the 
open-label extension of the TOMORROW trial, and 
in the other trials described above. In all these trials, 
specific recommendations were provided to the investiga-
tors for the management of adverse events of diarrhoea 
and hepatic enzyme elevations. Patients at an increased 
risk of bleeding (ie, with a genetic predisposition to 
bleeding, or requiring fibrinolysis, full-dose therapeutic 
anticoagulation, or high-dose antiplatelet therapy) were 
not eligible to participate in these trials. Patients with a 
recent history of thrombotic events, including stroke and 
transient ischaemic attacks (previous year), myocardial 
infarction (MI; previous 6 months) and unstable angina 
(previous month), were excluded from the randomised 
placebo-controlled trials. Patients who developed new 
major thromboembolic events after completion of the 
INPULSIS trials were excluded from INPULSIS-ON.
For the purposes of this analysis, patients treated with 
≥1 dose of nintedanib 150 mg two times per day in the 
trials described above were pooled to form a pooled 
nintedanib group. Patients who were randomised to 
placebo or nintedanib 50 mg once a day, 50 mg two times 
per day, or 100 mg two times per day in the double-blind 
phase of the TOMORROW trial were not included in 
the pooled nintedanib population, even if they received 
a dose of nintedanib 150 mg two times per day in the 
open-label extension. Patients who switched from 
blinded placebo to open-label nintedanib in INPUL-
SIS-ON and the Phase IIIb trial were analysed as part of 
the pooled nintedanib population from their first dose 
of nintedanib. Patients treated with ≥1 dose of placebo in 
the TOMORROW, INPULSIS and Phase IIIb trials were 
pooled to form a pooled placebo group.
Patient and public involvement
Patients were not involved in the design, recruitment to 
or conduct of the studies included in this analysis.
safety and tolerability
All adverse events reported by investigators, irrespective 
of causality, were included in this analysis. Adverse events 
were coded according to preferred terms in the Medical 
Dictionary for Regulatory Activities (MedDRA) version 
19.1. Safety data from INPULSIS-ON and the Phase IIIb 
trial were based on a snapshot conducted on 15 April 2017. 
The other trials had been completed by this date, but the 
MedDRA coding was updated to obtain consistent coding 
within the pooled population. Based on the mechanism 
of action of nintedanib, bleeding, major adverse cardio-
vascular events (MACE), MI and hepatic enzyme eleva-
tions were considered of particular interest. Bleeding was 
based on the standardised MedDRA query (SMQ) ‘haem-
orrhage terms (excluding laboratory terms)’. MACE were 
based on fatal adverse events in the MedDRA system organ 
classes ‘cardiac disorders’ and ‘vascular disorders’; fatal 
and non-fatal events in the subordinate SMQ ‘myocar-
dial infarction’; stroke based on selected preferred terms 
from the subordinate SMQs ‘haemorrhagic cerebrovas-
cular conditions’ and ‘ischaemic cerebrovascular condi-
tions’; and the MedDRA preferred terms ‘sudden death’, 
‘cardiac death’ and ‘sudden cardiac death’. MI was based 
on the subordinate SMQ ‘myocardial infarction (narrow 
definition)’. Hepatic enzyme elevations were based on a 
list of MedDRA preferred terms.
Event rates per 100 patient exposure-years were calcu-
lated based on adverse events with onset after the first 
dose and up to 28 days (or 14 days in the TOMORROW 
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Figure 1 Patients treated with nintedanib 150 mg two times per day and placebo who comprised the pooled populations.
trial) after the last dose of study drug. Analyses were 
descriptive.
survival
Survival data from INPULSIS-ON and the Phase IIIb 
trial were based on a snapshot conducted on 15 April 
2017. The other trials had been completed by this date. 
Weibull13 and exponential14 parametric survival distribu-
tions were fit to pooled Kaplan-Meier survival data for 
patients treated with nintedanib 150 mg two times per day 
and placebo and extrapolated to estimate life expectancy 
over the long term. The extent to which these statistical 
models fit the data was estimated using Akaike’s informa-
tion criterion. The estimated survival of patients treated 
with nintedanib and placebo was calculated from the 
area under the curve. Survival time was estimated from 
randomisation in the double-blind placebo-controlled 
trials and from the first intake of nintedanib if started in 
the open-label trials.
results
Patients
A total of 1126 patients treated with nintedanib 150 mg 
two times per day and 565 patients treated with placebo 
comprised the pooled populations (figure 1). Base-
line characteristics were generally similar between the 
nintedanib and placebo groups (table 1). In the pooled 
nintedanib population, the majority of patients were 
male (78.3%) and white (61.7%); at baseline, mean (SD) 
age was 66.9 (8.1) years, FVC was 78.7 (18.4)% predicted 
and DLco was 48.2 (13.5)% predicted.
exposure
The mean (SD) exposure to nintedanib in the pooled 
population was 27.7 (20.5) months (online supplementary 
table S1). The median exposure to nintedanib was 22.5 
months and the maximum was 93.1 months. Exposure 
to nintedanib in the individual trials is summarised in 
the online supplementary table S2. In total, 458 (40.7%) 
patients in the pooled nintedanib population had ≥1 
dose reduction from 150 to 100 mg two times per day. 
Median exposures to nintedanib 150 and 100 mg two 
times per day were 14.2 and 8.3 months, respectively.
Mean (SD) exposure to placebo in the pooled popu-
lation was 10.4 (3.1) months. The median exposure to 
placebo was 11.9 months and the maximum was 13.1 
months.
Adverse events
Diarrhoea was the most frequent adverse event in 
patients treated with nintedanib. In the pooled 
nintedanib population, the event rate of diarrhoea was 
76.5 events per 100 patient exposure-years, which was 
lower than that reported in nintedanib-treated patients 
in the INPULSIS trials (112.6 events per 100 patient 
exposure-years) but higher than that in the pooled 
placebo population (25.6 events per 100 patient expo-
sure-years) (table 2). The event rate of hepatic enzyme 
elevation was 12.1 events per 100 patient exposure-years 
in the pooled nintedanib population compared with 3.4 
events per 100 patient exposure-years in placebo-treated 
patients in the INPULSIS trials (table 3). The event rate 
of bleeding was 9.3 events per 100 patient exposure-years 
in the pooled nintedanib population compared with 
10.2 events per 100 patient exposure-years in place-
bo-treated patients in the INPULSIS trials (table 3). The 
most common bleeding events in the pooled nintedanib 
population were epistaxis (3.1 events per 100 patient 
exposure-years) and haemoptysis (1.3 events per 100 
patient exposure-years). The event rates for MACE and 
MI in the pooled nintedanib population were 3.7 and 
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Table 1 Baseline characteristics
Pooled population 
treated with nintedanib 
(n=1126)
Pooled population 
treated with placebo
(n=565)
INPULSIS trials
Nintedanib 
(n=638) Placebo (n=423)
Age, years, mean (SD) 66.9 (8.1) 66.6 (8.2) 66.6 (8.1) 67.0 (7.9)
Male, n (%) 882 (78.3) 434 (76.8) 507 (79.5) 334 (79.0)
Race, n (%)
  White 695 (61.7) 367 (65.0) 360 (56.4) 248 (58.6)
  Asian 316 (28.1) 151 (26.7) 194 (30.4) 128 (30.3)
  Black 2 (0.2) 0 (0.0) 2 (0.3) 0 (0.0)
  Missing* 113 (10.0) 47 (8.3) 82 (12.9) 47 (11.1)
Body mass index, kg/m2, mean (SD) 27.9 (4.6) 27.9 (4.6) 28.1 (4.6) 27.6 (4.6)
Smoking history, n (%)
  Former smoker 768 (68.2) 374 (66.2) 435 (68.2) 283 (66.9)
  Never smoker 313 (27.8) 167 (29.6) 174 (27.3) 122 (28.8)
  Current smoker 45 (4.0) 24 (4.2) 29 (4.5) 18 (4.3)
FVC, % predicted, mean (SD) 78.7 (18.4) 79.5 (18.3) 79.7 (17.6) 79.3 (18.2)
FEV1/FVC, %, mean (SD) 81.6 (6.4) 81.7 (5.9) 81.7 (5.8) 81.7 (6.0)
DLco, % predicted, mean (SD) 48.2 (13.5)† 47.7 (13.5) 47.4 (13.5) 47.0 (13.4)
*In France, regulation did not permit the collection of data on race.
†n=821 (DLco was not collected at the start of the open-label extensions of TOMORROW and INPULSIS-ON).
DLco, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
1.1 events per 100 patient exposure-years, compared 
with 2.7 and 0.5 events per 100 patient exposure-years, 
respectively, in placebo-treated patients in the INPULSIS 
trials (table 3).
The event rates of adverse events that led to permanent 
dose reduction or permanent treatment discontinuation 
in the pooled nintedanib population were generally 
lower than those reported in nintedanib-treated patients 
in the INPULSIS trials (online supplementary tables 
S3 and S4). In the pooled nintedanib population, the 
event rate of adverse events that led to permanent dose 
reduction was 12.8 events per 100 patient exposure-years. 
Diarrhoea was the most frequent adverse event that led 
to permanent dose reduction of nintedanib (at a rate 
of 7.4 events per 100 patient exposure-years). The event 
rate of adverse events that led to permanent discontin-
uation of nintedanib was 23.8 events per 100 patient 
exposure-years. The event rate of diarrhoea that led to 
permanent discontinuation of nintedanib was 3.6 events 
per 100 patient exposure-years.
The event rate of serious adverse events in the pooled 
nintedanib population was 64.6 events per 100 patient 
exposure-years (online supplementary table S5). Progres-
sion of IPF, which included disease worsening and acute 
exacerbations, was the most frequent serious adverse 
event reported in the pooled nintedanib population. 
This was reported at a lower rate than in placebo-treated 
patients in the INPULSIS trials (8.4 vs 11.4 events per 100 
patient exposure-years).
survival
The numbers of deaths in the individual trials are shown 
in the online supplementary tables S6 and S7. Based on 
the Weibull distribution, mean (95% CI) survival was 
estimated as 11.6 (9.6, 14.1) years in nintedanib-treated 
patients and 3.7 (2.5, 5.4) years in placebo-treated 
patients (figure 2A). Median survival was estimated as 8.5 
years and 3.3 years in these groups, respectively. Based on 
the exponential distribution, mean (95% CI) survival was 
estimated as 13.1 (11.6, 14.9) years in nintedanib-treated 
patients and 10.1 (7.8, 13.0) years in placebo-treated 
patients (figure 2B). Median survival was estimated as 9.1 
years and 7.0 years in these groups, respectively. Model 
fit based on Akaike’s information criterion was superior 
(lower) for the Weibull model compared with the expo-
nential model in placebo-treated patients (428 vs 440) 
but not in nintedanib-treated patients (1593 for both 
models).
dIscussIon
We conducted a comprehensive analysis of the safety 
and tolerability of nintedanib using pooled data from six 
clinical trials conducted in patients with IPF and mild or 
moderate impairment in lung function. Based on data 
from 1126 patients followed up for a mean of 28 months 
and a maximum of 93 months, nintedanib had a safety 
and tolerability profile that was manageable for most 
patients, with adverse events that were mainly gastrointes-
tinal in nature. As expected, the most frequently reported 
adverse event was diarrhoea, which was reported at an 
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Table 2 Adverse events reported in the pooled population treated with nintedanib and in nintedanib-treated and placebo-
treated patients in the INPULSIS trials
Pooled population treated 
with nintedanib (n=1126)
INPULSIS
Nintedanib (n=638) Placebo (n=423)
Events, 
n
Event rate
(per 100 patient 
exposure-years)
Events, 
n
Event rate
(per 100 patient 
exposure-years)
Events, 
n
Event rate
(per 100 patient 
exposure-
years)
Diarrhoea 2084 76.5 671 112.6 106 25.6
Nausea 489 18.0 208 34.9 29 7.0
Nasopharyngitis 410 15.1 117 19.6 91 22.0
Bronchitis 395 14.5 92 15.5 62 15.0
Cough 359 13.2 96 16.1 67 16.2
Progression of IPF* 350 12.9 70 11.8 73 17.7
Vomiting 304 11.2 102 17.1 11 2.7
Upper respiratory tract infection 274 10.1 72 12.1 55 13.3
Dyspnoea 253 9.3 50 8.4 51 12.3
Weight decreased 230 8.4 64 10.7 15 3.6
Decreased appetite 225 8.3 75 12.6 26 6.3
Abdominal pain 168 6.2 68 11.4 10 2.4
Lower respiratory tract infection 164 6.0 47 7.9 22 5.3
Respiratory tract infection 160 5.9 33 5.5 28 6.8
Pneumonia 159 5.8 40 6.7 31 7.5
Fatigue 153 5.6 44 7.4 35 8.5
Adverse events with event rate >5 per 100 patient exposure-years in the pooled population are shown.
*Corresponds to MedDRA preferred term ‘IPF’, which included disease worsening and acute exacerbations.
IPF, idiopathic pulmonary fibrosis; MedDRA, Medical Dictionary for Regulatory Activities.
Table 3 Adverse events of particular interest in the pooled population treated with nintedanib and in the INPULSIS trials
Pooled population treated 
with nintedanib (n=1126)
INPULSIS
Nintedanib (n=638) Placebo (n=423)
Events,
n
Event rate
(per 100 patient 
exposure-years)
Events, 
n
Event rate
(per 100 patient 
exposure-years)
Events, 
n
Event rate
(per 100 patient 
exposure-
years)
Hepatic enzyme elevation 330 12.1 132 22.2 14 3.4
Bleeding 253 9.3 94 15.8 42 10.2
MACE 101 3.7 26 4.4 11 2.7
Myocardial infarction 30 1.1 11 1.8 2 0.5
MACE, major adverse cardiovascular events.
event rate of 76.5 events per 100 patient exposure-years 
but led to permanent treatment discontinuation at a much 
lower rate (3.6 events per 100 patient exposure-years). 
Diarrhoea is a well-known side effect of tyrosine kinase 
inhibitors but the precise mechanism/s that cause it are 
unclear.15 It is recommended that patients who experi-
ence diarrhoea while taking nintedanib should ensure 
adequate hydration and take antidiarrheal medicine (eg, 
loperamide) straight away.16 17 If diarrhoea persists, dose 
adjustment is recommended, and indeed in our analysis, 
diarrhoea was the most common reason for permanent 
dose reduction of nintedanib. Dose adjustment is also 
recommended to treat nausea and vomiting.16 Impor-
tantly, data from the INPULSIS trials showed that the 
rate of decline in FVC was similar in patients treated with 
nintedanib irrespective of whether they had dose reduc-
tions and/or treatment interruptions to manage adverse 
events.18
Elevations in hepatic enzymes (alanine aminotrans-
ferase and aspartate aminotransferase) and bilirubin 
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Figure 2 Estimated time to death using (A) the Weibull 
distribution and (B) exponential distribution.
occur in a small proportion of patients treated with 
nintedanib and cases of drug-induced liver injury have 
been reported.16 It is recommended that hepatic enzymes 
be monitored prior to the initiation of nintedanib, at 
regular intervals during the first 3 months of treatment, 
and periodically thereafter.16 In the pooled nintedanib 
population, hepatic enzyme elevations (based on a list 
of MedDRA preferred terms) occurred at a rate of 12.1 
events per 100 patient exposure-years, compared with 3.4 
events per 100 patient exposure-years in placebo-treated 
patients in the INPULSIS trials. None of the nintedan-
ib-treated patients with hepatic enzyme elevations devel-
oped liver failure and there were no liver-related deaths.
Like other inhibitors of the vascular endothelial growth 
factor receptor19 nintedanib has been associated with an 
increased risk of bleeding.20 The event rate of bleeding 
observed in the pooled population of nintedanib-treated 
patients was no higher than that observed in place-
bo-treated patients in the INPULSIS trials (9.3 vs 10.2 
events per 100 patient exposure-years, respectively). The 
lower event rate of bleeding in the pooled nintedanib 
population compared with nintedanib-treated patients 
in the INPULSIS trials suggests that the risk of bleeding 
events does not increase with more prolonged treatment. 
However, it should be noted that patients at known risk 
of bleeding, including those treated with full-dose antico-
agulants or high-dose antiplatelet therapy, were excluded 
from these trials. It is recommended that nintedanib be 
used in patients with known risk of bleeding only if the 
anticipated benefit outweighs the potential risk.16
Event rates of MACE and MI in the pooled nintedanib 
population were low and consistent with those observed 
in nintedanib-treated patients in the INPULSIS trials.9 In 
postmarketing surveillance data collected in the USA in 
the year following the launch of nintedanib as a treat-
ment for IPF, the incidence rates of MACE and MI were 
lower than those in nintedanib-treated patients in the 
INPULSIS trials21; further, the incidence of MI was lower 
than that observed in an analysis of insurance claims data 
from 9286 US patients with IPF.22 These data are reas-
suring with regard to the cardiovascular safety profile of 
nintedanib.
Modelling and extrapolation of survival data from the 
clinical trials included in this pooled analysis suggest 
that nintedanib extends life expectancy in patients with 
IPF. Median survival based on the better fitting statis-
tical model (Weibull) was extended by approximately 5 
years in patients treated with nintedanib compared with 
placebo. Clearly such extrapolations have limitations and 
should be interpreted with caution, but these data add 
to the growing body of evidence suggesting that antifi-
brotic therapies are associated with improved survival in 
patients with IPF.6 12 23–26
Strengths of these analyses include the use of a large 
and well-characterised cohort of patients participating 
in prospectively designed clinical trials and a maximum 
treatment duration of over 7 years. Limitations include 
the exclusion of patients who had severe impairment in 
lung function, had certain comorbidities, or who were 
using full-dose anticoagulants from these trials, and 
selection bias in the patients who entered the open-label 
extension trials, in that these patients were likely to have 
milder disease and to be better able to tolerate nintedanib 
than those who discontinued during the parent trial.
In conclusion, in 1126 patients with IPF treated with 
nintedanib for a mean duration of 28 months, adverse 
events were manageable for most patients. The adverse 
event profile of nintedanib in the pooled population 
was consistent with that observed in the INPULSIS trials, 
with no new safety signals observed. Exploratory analyses 
based on extrapolation of survival data suggested that 
patients with IPF who are treated with nintedanib have 
longer life expectancy than those who do not receive 
treatment.
Author affiliations
1Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
2APHP, Service de Pneumologie, Hôpital Bichat, Paris, France; Université Paris 
Diderot, Paris, France
3QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
4Diffuse Lung Diseases and Respiratory Failure, National Hospital 
Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
5Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, 
Germany
6Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
7Fondazione Policlinico A Gemelli IRCCS, Università Cattolica del Sacro Cuore, 
Rome, Italy
Lancaster L, et al. BMJ Open Resp Res 2019;6:e000397. doi:10.1136/bmjresp-2018-000397 7
Open access
Acknowledgements Medical writing assistance, supported financially by 
Boehringer Ingelheim, was provided by Julie Fleming and Wendy Morris of 
FleishmanHillard Fishburn, London, UK, during the preparation of this manuscript. 
The authors received no direct compensation for the development of the 
manuscript, were fully responsible for all content and editorial decisions, were 
involved at all stages of manuscript development and have approved the final 
version. Boehringer Ingelheim was given the opportunity to review the manuscript 
for medical and scientific accuracy as well as intellectual property considerations.
contributors All authors were involved in planning the analyses, in the 
interpretation of data and in drafting the manuscript.
Funding The trials that provided data for these analyses were funded by 
Boehringer Ingelheim.
competing interests LLa has served on advisory boards for Genentech, Global 
Blood Therapeutics, Boehringer Ingelheim, Veracyte, Theravance, Magnolia 
Therapeutics, Galapagos and Bellerophon; has provided disease state education 
for Genentech and Boehringer Ingelheim; has served as a principal investigator 
in clinical trials in IPF and other ILDs for Genentech, Global Blood Therapeutics, 
Celgene, FibroGen, Stromedix, Veracyte, Afferent, Merck, Bellerophon, Novartis, 
Galapagos, Galecto, the National Institutes of Health and Boehringer Ingelheim. 
BC has received grants from Apellis and MedImmune; grants and personal fees 
from Boehringer Ingelheim and Roche; and personal fees from AstraZeneca and 
Sanofi. PH has served on advisory boards for Actelion, AstraZeneca, Boehringer 
Ingelheim, GlaxoSmithKline, Teva and Trudell; served as a principal investigator in 
clinical trials in IPF for Boehringer Ingelheim and Prometic; and provided disease 
state education in IPF/ILDs for Boehringer Ingelheim and Roche. YI has served 
on advisory boards for Boehringer Ingelheim and reports lecture and advisory 
fees from Boehringer Ingelheim, Shionogi & Co, Ltd, Takeda, Nobel Pharma, 
Novartis, Serendex, Bayer, Chugai and Daiichi Sankyo. LR has served on advisory 
boards for Anthera, Asahi-Kasei, AstraZeneca, Bayer, Boehringer Ingelheim, 
Biogen Idec, FibroGen, GlaxoSmithKline, ImmuneWorks, InterMune, MedImmune, 
PatientsLikeMe, Promedior, Roche, Sanofi-Aventis, Takeda and UCB; received 
grants from InterMune, the Italian Ministry of Health, the National Drug Agency 
(Italy), the National Research Council (Italy) and Roche; and received speaker fees 
from Boehringer Ingelheim, Cipla, InterMune and Roche. DW, LLo, MQ and SS are 
employees of Boehringer Ingelheim.
Patient consent for publication Not required.
ethics approval All clinical trial protocols were approved by an independent ethics 
committee or institutional review board at every participating institution.
Provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement Data are available uponon request. A request can 
be submitted via https:// trials. boehringer- ingelheim. com/ trial_ results/ clinical_ 
submission_ documents. html.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
RefeRenCes
 1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic 
pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice 
guideline. Am J Respir Crit Care Med 2018;198:e44–68.
 2. Kreuter M, Swigris J, Pittrow D, et al. Health related quality of life 
in patients with idiopathic pulmonary fibrosis in clinical practice: 
insights-IPF registry. Respir Res 2017;18.
 3. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, 
prevalence, and clinical course of idiopathic pulmonary fibrosis: a 
population-based study. Chest 2010;137:129–37.
 4. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and 
prognosis of idiopathic pulmonary fibrosis in the new millennium. 
Chest 2011;140:221–9.
 5. Raghu G, Chen S-Y, Yeh W-S, et al. Idiopathic pulmonary 
fibrosis in US Medicare beneficiaries aged 65 years and older: 
incidence, prevalence, and survival, 2001-11. Lancet Respir Med 
2014;2:566–72.
 6. Guenther A, Krauss E, Tello S, et al. The European IPF registry 
(eurIPFreg): baseline characteristics and survival of patients with 
idiopathic pulmonary fibrosis. Respir Res 2018;19.
 7. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine 
kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 
2011;365:1079–87.
 8. Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of 
patients with idiopathic pulmonary fibrosis with nintedanib: results 
from the tomorrow trial and its open-label extension. Thorax 
2018;73:581–3.
 9. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety 
of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 
2014;370:2071–82.
 10. Crestani B, Huggins JT, Kaye M, et al. Long-term safety and 
tolerability of nintedanib in patients with idiopathic pulmonary 
fibrosis: results from the open-label extension study, INPULSIS-ON. 
Lancet Respir Med 2019;7:60–8.
 11. Lancaster L, Ilowite J, Trampisch M, et al. Effect of nintedanib on 
disease progression: results from a phase IIIB trial in patients with 
idiopathic pulmonary fibrosis. Nashville, TN, USA: Poster presented 
at the Pulmonary Fibrosis Foundation, 2017.
 12. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients 
with idiopathic pulmonary fibrosis: Combined evidence from the 
TOMORROW and INPULSIS(®) trials. Respir Med 2016;113:74–9.
 13. Collett D. Modelling survival data in medical research. London: 
Chapman and Hall, 1994.
 14. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life 
expectancy (the "DEALE"). I. Validation of the method. Am J Med 
1982;73:883–8.
 15. Bowen JM. Mechanisms of TKi-induced diarrhea in cancer patients. 
Curr Opin Support Palliat Care 2013;7:162–7.
 16. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV® (nintedanib) 
prescribing information, 2018. Available: http:// bidocs. boehringer- 
ingelheim. com/ BIWebAccess/ ViewServlet. ser? docBase= renetnt& 
folderPath=/ Prescribing+ Information/ PIs/ Ofev/ ofev. pdf [Accessed 30 
Nov 2018].
 17. Bendstrup E, Wuyts W, Alfaro T, et al. Nintedanib in idiopathic 
pulmonary fibrosis: practical management recommendations for 
potential adverse events. Respiration 2019;97:173–84.
 18. Maher TM, Inoue Y, Case AH, et al. Effect of dose reductions and/or 
interruptions on the efficacy of nintedanib in patients with idiopathic 
pulmonary fibrosis (IPF): Subgroup analysis of the INPULSIS trials. 
Washington, DC, USA: Poster presented at the American Thoracic 
Society International Conference, 2017.
 19. Chen HX, Cleck JN. Adverse effects of anticancer agents that target 
the VEGF pathway. Nat Rev Clin Oncol 2009;6:465–77.
 20. Corte T, Bonella F, Crestani B, et al. Safety, tolerability and 
appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir 
Res 2015;16.
 21. Noth I, Oelberg D, Kaul M, et al. Safety and tolerability of nintedanib 
in patients with idiopathic pulmonary fibrosis in the USA. Eur Respir 
J 2018;52. doi:10.1183/13993003.02106-2017. [Epub ahead of print: 
27 Jul 2018].
 22. Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic 
pulmonary fibrosis. J Med Econ 2012;15:829–35.
 23. Fisher M, Nathan SD, Hill C, et al. Predicting life expectancy for 
pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec 
Pharm 2017;23(3-b Suppl):S17–S24.
 24. HE J, Glaspole I, Grainge C, et al. Baseline characteristics of 
idiopathic pulmonary fibrosis: analysis from the Australian idiopathic 
pulmonary fibrosis registry. Eur Respir J 2017;49.
 25. Rinciog C, Watkins M, Chang S, et al. A cost-effectiveness 
analysis of nintedanib in idiopathic pulmonary fibrosis in the UK. 
Pharmacoeconomics 2017;35:479–91.
 26. Vašáková M. Real world idiopathic pulmonary fibrosis in the Empire 
registry. Poster presented at the European Respiratory Society 
International Congress, 2018.
